Home
Search
Policy

Policy

Insights
Browse all insights
News
Browse all news
Biotechnology Innovation Organization (BIO) Launches the BIO Investment Council (BIC) to Accelerate Capital Formation
January 7, 2026
BIO Statement on Changes Announced to the U.S. Childhood Vaccine Schedule
January 5, 2026
CSBA Letter to Congressional Leaders on PBM, PPRV, and SBIR
December 8, 2025
BIO Statement on December 2025 ACIP Meeting
December 5, 2025
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
CSBA Letter to Congressional Leaders on PBM, PPRV, and SBIR
December 8, 2025
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to urge swift congressional action on three bipartisan…
BIO's Comments on Advisory Committee on Immunization Practices (ACIP) - December 2025
December 4, 2025
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in advance of…
Testimony of BIO President & CEO John F. Crowley before the Senate Health, Education, Labor, and Pensions (HELP) Committee: “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients”
October 29, 2025
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000 biotechnology companies, academic institutions, and research…
Co-Pay Accumulator Programs
Insurers and PBMs are implementing “co-pay accumulator” programs – an effort to prevent funds provided by manufacturer assistance programs from…
International Reference Pricing
Adopting foreign price controls on innovative medicines would severely chill investment in new cures and therapies for diseases and jeopardize access…